CureVac’s (CVAC) Market Outperform Rating Reiterated at JMP Securities

CureVac (NASDAQ:CVAC)‘s stock had its “market outperform” rating reiterated by JMP Securities in a report issued on Wednesday, Benzinga reports. They presently have a $18.00 price target on the stock. JMP Securities’ price objective indicates a potential upside of 476.92% from the stock’s current price.

A number of other research firms also recently commented on CVAC. Guggenheim restated a “neutral” rating on shares of CureVac in a research note on Friday, April 5th. SVB Leerink downgraded shares of CureVac from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $12.00 to $4.00 in a research note on Thursday, April 25th. Finally, Leerink Partnrs downgraded shares of CureVac from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, CureVac currently has an average rating of “Hold” and an average target price of $10.00.

CureVac Price Performance

Shares of NASDAQ CVAC opened at $3.12 on Wednesday. The firm has a market cap of $698.51 million, a PE ratio of -2.35 and a beta of 2.64. The company has a current ratio of 2.25, a quick ratio of 2.09 and a debt-to-equity ratio of 0.08. CureVac has a 1-year low of $2.21 and a 1-year high of $10.77. The company has a fifty day moving average price of $3.47 and a 200 day moving average price of $3.45.

CureVac (NASDAQ:CVAC) last announced its earnings results on Thursday, May 23rd. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.12). CureVac had a negative return on equity of 49.22% and a negative net margin of 463.49%. The company had revenue of $13.43 million during the quarter, compared to analyst estimates of $14.51 million. Research analysts predict that CureVac will post -1.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CureVac

Institutional investors and hedge funds have recently modified their holdings of the company. Vontobel Holding Ltd. bought a new stake in shares of CureVac in the 4th quarter valued at about $45,000. Ballentine Partners LLC bought a new stake in shares of CureVac in the 1st quarter valued at about $38,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of CureVac in the 4th quarter valued at about $68,000. International Assets Investment Management LLC bought a new stake in shares of CureVac in the 4th quarter valued at about $71,000. Finally, Aristides Capital LLC bought a new stake in shares of CureVac in the 4th quarter valued at about $100,000. 17.26% of the stock is owned by institutional investors.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.